KM Research Hub
← 返回论文库
待处理 入排:排除 图源:待检查

Are we ready for deintensification in human papillomavirus-positive oropharyngeal carcinomas?

Shao Hui Huang, Ezra Hahn, Rohan Salunkhe, Marc Vincent N Barcelona, Brian O'Sullivan

Curr Opin Otolaryngol Head Neck Surg 31(2) 118-128

PMID36912224
PMCID-
DOI10.1097/MOO.0000000000000871
发表日期2023-03-13
摘要

摘要

PURPOSE OF REVIEW: Excellent outcomes following contemporary treatment of human papillomavirus (HPV)-positive oropharyngeal carcinoma (HPV+ OPC) have prompted the exploration of deintensification approaches to minimize treatment-related toxicities. This review describes the landscape of deintensification to date (up to November 2022). RECENT FINDINGS: Although several deintensification trials have been published, none are practice changing. Three phase III randomized-controlled trials studying cetuximab and radiation therapy vs. standard chemoradiotherapy all showed inferior outcomes. Although some phase II trials reported favourable outcomes, they are often single-arm trials without an adequate control arm, thereby limiting the ability to modify practice. SUMMARY: Substantial effort has been expended to explore deintensification options for selected HPV+ OPC patients aiming to avoid unnecessary toxicity. Strategies have included replacing cisplatin with cetuximab, reduced chemotherapy or radiotherapy intensity, reduction of radiotherapy volumes and risk stratification after trans-oral surgery or following induction chemotherapy. Challenges remain in the current deintensification landscape, including identifying the most suitable candidates along with a choice of most appropriate deintensification strategies. Promising selection criteria included either static baseline features or kinetic characteristics of clinical-biological parameters. Practice-changing trials remain elusive, and the search continues to attempt optimization of the therapeutic ratio for these patients.

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。